| Width: | 180 |
| Tradename: | Zunveyl |
| Dailymedid: | Benzgalantamine |
| Routes Of Administration: | By mouth |
| Class: | Cholinesterase inhibitor |
| Atc Prefix: | None |
| Legal Us: | Rx-only |
| Legal Us Comment: | [1] |
| Cas Number: | 224169-27-1 |
| Cas Number2: | 1542321-58-3 |
| Unii: | XOI2Q0ZF7G |
| Unii2: | LN7PMJ4P57 |
| Kegg: | D12930 |
| Kegg2: | D12931 |
| Chembl: | 5095056 |
| Synonyms: | ALPHA-1062 |
| C: | 24 |
| H: | 25 |
| N: | 1 |
| O: | 4 |
| Smiles: | COc1ccc2c3c1O[C@H]1C[C@@H](OC(=O)c4ccccc4)C=C[C@@]31CCN(C)C2 |
| Stdinchi: | 1S/C24H25NO4/c1-25-13-12-24-11-10-18(28-23(26)16-6-4-3-5-7-16)14-20(24)29-22-19(27-2)9-8-17(15-25)21(22)24/h3-11,18,20H,12-15H2,1-2H3/t18-,20-,24-/m0/s1 |
| Stdinchikey: | JKVNJTYHRABHIY-WXVUKLJWSA-N |
Benzgalantamine, sold under the brand name Zunveyl, is a medication used for the treatment of mild to moderate dementia of the Alzheimer's type. It is a cholinesterase inhibitor. Benzgalantamine is a prodrug of galantamine.
The most common side effects include nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite.
Benzgalantamine was approved for medical use in the United States in July 2024.[2] [3]
Benzgalantamine is indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults.
The most common side effects include nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite.
Benzgalantamine was approved for medical use in the United States in July 2024.
Benzgalantamine is the international nonproprietary name.[4]